Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HTI immunogen
- Development stage
- Unknown
- Lead developer
- Aelix Therapeutics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **HTI immunogen** is a synthetic vaccine antigen designed to elicit robust T-cell responses targeting functionally constrained regions of HIV-1, including fragments from Gag, Pol, Vif, and Nef proteins selected based on their association with natural viral control in elite controllers. Developed by IrsiCaixa researchers led by Dr. Christian Brander and advanced by AELIX Therapeutics, it is delivered via heterologous prime-boost regimens using DNA.HTI, modified vaccinia Ankara (MVA.HTI), and chimpanzee adenovirus (ChAdOx1.HTI) vectors to stimulate broad, polyfunctional CD4+ and CD8+ T-cell immunity aimed at enhancing virologic control in antiretroviral therapy (ART)-suppressed individuals with HIV, potentially as a backbone for functional HIV cures.[1][3][5]
- Other names
- HIVACAT T-cell immunogen
02
Targets
Env (HIV-1 envelope glycoprotein)Gag-Pol (HIV-1 gag-pol polyprotein)Gag (HIV-1 Gag polyprotein)Nef (HIV-1 Nef)Human immunodeficiency virus type 1 reverse transcriptaseVif (HIV-1 Vif)
Beyond the preview
Go deeper on HTI immunogen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HTI immunogen.